Comparative evaluation of amisulpride and escitalopram on Hamilton anxiety rating scale among depression patients in a tertiary care teaching hospital in Nepal.
dc.contributor.author | Kaul, Vijay | |
dc.contributor.author | Dutta, Shakti B | |
dc.contributor.author | Beg, Mirza A | |
dc.contributor.author | Bawa, Shalu | |
dc.contributor.author | Anjoom, Mohammed | |
dc.contributor.author | Singh, Nand K | |
dc.contributor.author | Dutta, Srihari | |
dc.date.accessioned | 2015-11-04T10:46:59Z | |
dc.date.available | 2015-11-04T10:46:59Z | |
dc.date.issued | 2015-03 | |
dc.description.abstract | Background: Depression is an important global public health problem and is a major cause of disability and premature death. The present study was conducted to compare effi cacy and safety of amisulpride and escitalopram on Hamilton anxiety rating scale (HAM-A) among depression patients in a tertiary care teaching hospital in Nepal. Methods: The study was conducted in patients for 1-year in the Department of Neuropsychiatry, Nepalgunj Medical College and Teaching Hospital. A total of 117 depression patients were divided into two groups. Group I (58 patients) received amisulpride tablet at a dose of 50 mg/day and Group II (59 patients) were given escitalopram at a dose of 10 mg/day. The patients were required to follow-up at 4, 8 and 15 weeks. The effi cacy of the drugs was calculated by HAM-A. Adverse drug reactions (ADRs) were monitored at every follow-up. Appropriate statistical tools using Graphpad instat 3.0 were used for analysis p<0.05 was considered signifi cant. Results: HAM-A score in group receiving amisulpride at 0 and 15 weeks was 19.83±0.33 and 8.17±0.32 (p<0.0001). HAM-A score in group receiving escitalopram at 0 and 15 weeks was 20.76±0.28 and 8.98±0.24 (p<0.0001). Gastrointestinal disturbances, sexual disturbances, amenorrhea, lactation, agitation, and insomnia were the commonly encountered ADRs. Conclusion: Both amisulpride and escitalopram were highly effective in the treatment of anxiety in depression patients during the study period. Further, more clinical studies with longer follow-up duration are needed to substantiate the therapeutic effects of amisulpride. | en_US |
dc.identifier.citation | Kaul Vijay, Dutta Shakti B, Beg Mirza A, Bawa Shalu, Anjoom Mohammed, Singh Nand K, Dutta Srihari. Comparative evaluation of amisulpride and escitalopram on Hamilton anxiety rating scale among depression patients in a tertiary care teaching hospital in Nepal. International Journal of Basic & Clinical Pharmacology. 2015 Mar-Apr; 4(2): 349-353. | en_US |
dc.identifier.issn | 2319-2003 | |
dc.identifier.issn | 2279-0780 | |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/165072 | |
dc.language.iso | en | en_US |
dc.source.uri | https://www.ijbcp.com/?mno=179890 | en_US |
dc.subject | Depression | en_US |
dc.subject | Amisulpride | en_US |
dc.subject | Escitalopram | en_US |
dc.subject | Hamilton anxiety rating scale | en_US |
dc.title | Comparative evaluation of amisulpride and escitalopram on Hamilton anxiety rating scale among depression patients in a tertiary care teaching hospital in Nepal. | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijbcp2015v4n2p349.pdf
- Size:
- 204.47 KB
- Format:
- Adobe Portable Document Format
- Description:
- Research article
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: